In particular, KRAS G12C mutant-specific inhibitory molecules revealed an encouraging antitumor effect in preclinical models using cell lines of patient-derived samples as well as in phase I clinical trials with lung and CRC patients [15]. The gene discussed is KRAS; the disease is colorectal carcinoma.